Histology of Autoimmune Hepatitis and its Variants

Clinics in Liver Disease

Volumn 14, Issue 4, 2010, Pages 577-590

  Guindi, Maha ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Autoimmune hepatitis; Autoimmune liver disease; Biopsy; Chronic hepatitis; Histology; Overlap syndrome

Indexed keywords

MITOCHONDRION ANTIBODY;

AUTOIMMUNE HEPATITIS; BILE DUCT INJURY; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; GIANT SYNCYTIAL MULTINUCLEATED HEPATOCYTE; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLAMMATORY INFILTRATE; LIVER CELL; LIVER CIRRHOSIS; LIVER HISTOLOGY; LIVER NECROSIS; PATHOLOGIST; PLASMA CELL; REVIEW; SCORING SYSTEM;

BIOPSY; CHOLANGITIS, SCLEROSING; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS, BILIARY;

EID: 78049487106     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2010.07.003     Document Type: Review

References (59)

1. Czaja A.J., Freese D.K. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002, 36:479-497.
2. Krawitt E.L. Autoimmune hepatitis. N Engl J Med 2006, 354:54-66.
3. Czaja Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl 2007, 13:953-955.
4. Johnson P.J., McFarlane I.G. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993, 18:998-1005.
5. Czaja A., Carpenter H.A. Validation of scoring system for diagnosis of autoimmune hepatitis. Dig Dis Sci 1996, 41:305-314.
6. Bianchi F.B., Cassani F., Lenzi M., et al. Impact of International Autoimmune Hepatitis Group scoring system in definition of autoimmune hepatitis-An Italian experience. Dig Dis Sci 1996, 41:166-171.
7. Toda G., Zeniya M., Watanabe F., et al. Present status of autoimmune hepatitis in Japan-correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis. J Hepatol 1997, 26:1207-1212.
8. Alvarez F., Berg P.A., Bianchi F.B., et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
9. Boberg K.M., Fausa O., Haaland T., et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996, 23:1369-1376.
10. Choi G., Peters M.G. The challenge of diagnosing autoimmune hepatitis: less is more. Hepatology 2008, 48(1):10-12.
11. Hennes E.M., Zeniya M., Czaja A.J., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
12. Dienes H.P. Viral and autoimmune hepatitis. Morphologic and pathogenetic aspects of cell damage in hepatitis with potential chronicity. Veroff Pathol 1989, 132:1-107.
13. Washington K.M. Autoimmune liver disease: overlap and outliers. Mod Pathol 2007, 20:S15-S30.
14. Theise N.D., Bodenheimer H.C., Ferrell L.D. Acute and chronic viral hepatitis. Ween's pathology of the liver 2007, 399-441. Churchill Livingstone, Edinburgh (UK). 5th edition. A.D. Burt, B.C. Porman, L.D. Ferrell (Eds.).
15. Ichiki Y., Aoki C.A., Bowlus C.L., et al. T-cell immunity in autoimmune hepatitis. Autoimmun Rev 2005, 4:315-321.
16. Nikias G.A., Batts K.P., Czaja A.J. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994, 21:866-871.
17. Burgart L.J., Batts K.P., Ludwig J., et al. Recent onset autoimmune hepatitis: biopsy findings and clinical correlations. Am J Surg Pathol 1995, 19:699-708.
18. Johnson P.J., McFarlane I.G., Alvarez F., et al. Meeting report. International Autoimmune Hepatitis Group. Hepatology 1993, 18:998-1005.
19. Pratt D.S., Fawaz K.A., Rabson A., et al. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology 1997, 113:664-668.
20. Bach N., Thung S.N., Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992, 15:572-577.
21. Czaja A.J., Carpenter H.A. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993, 105:1824-1832.
22. Carpenter H.A., Czaja A.J. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002, 6:397-417.
23. Czaja A.J., Carpenter H.A. Autoimmune hepatitis. Macsween's pathology of the liver 2007, 493-515. Churchill Livingstone, Edinburgh (UK). 5th edition. A.D. Burt, B.C. Porman, L.D. Ferrell (Eds.).
24. Devaney K., Goodman Z.D., Ishak K.G. Postinfantile giant-cell transformation in hepatitis. Hepatology 1992, 16:327-333.
25. Phillips M.J., Blendis L.M., Poucell S., et al. Syncytial giant-cell hepatitis. Sporadic hepatitis with distinctive pathological features, a severe clinical course, and paramyxoviral features. N Engl J Med 1991, 324:455-460.
26. Czaja A.J., Carpenter H.A. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001, 34:659-665.
27. Czaja A.J., Carpenter H.A., Santrach P.J., et al. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 1993, 104(6):1755-1761.
28. Czaja A.J. The variant forms of autoimmune hepatitis. Ann Intern Med 1996, 125(7):588-598.
29. Mehendiratta V., Mitroo P., Bombonati A., et al. Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 2009, 7(1):98-103.
30. O'Brien C., Joshi S., Feld J.J., et al. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008, 48(2):550-556.
31. Abe M., Onji M., Kawai-Ninomiya K., et al. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin Gastroenterol Hepatol 2007, 5:255-258.
32. Dai Y.D., Carayanniotis G., Sercarz E. Antigen processing by autoreactive B cells promotes determinant spreading. Cell Mol Immunol 2005, 2:169-175.
33. Vanderlugt C.L., Miller S.D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002, 2:85-95.
34. Demetris A.J., Sebagh M. Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis?. Liver Transpl 2008, 14:750-755.
35. Czaja A.J., Carpenter H.A. Histological findings in chronic hepatitis C with autoimmune features. Hepatology 1997, 26:459-466.
36. Kessel A., Toubi E. Chronic HCV-related autoimmunity: a consequence of viral persistence and lymphotropism. Curr Med Chem 2007, 14:547-554.
37. Czaja A.J., Davis G.L., Ludwig J., et al. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984, 4:622-627.
38. Czaja A.J., Ludwig J., Baggenstoss A.H., et al. Corticosteroid-treated chronic active hepatitis in remission. Uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981, 304:5-9.
39. Czaja A.J. Therapy of autoimmune hepatitis-state of the art. Immunology and liver, Falk Symposium 114 2000, 311-324. Kluwer Academic Publishers, BV, Dordrecht (The Netherlands). M.P. Manns, G. Paumgartner, U. Leuschner (Eds.).
40. Czaja A.J. Treatment of autoimmune hepatitis. Autoimmune liver disease 1998, 399-415. Elsevier Science Publishers, Amsterdam (The Netherlands). E.L. Krawitt, R.H. Wiesner (Eds.).
41. Stellon A.J., Keating J.J., Johnson P.J., et al. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988, 8:781-784.
42. Czaja A.J., Beaver S.J., Shiels M.T. Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis. Gastroenterology 1987, 92:215-219.
43. Davis G.L., Czaja A.J. Immediate and long-term results of corticosteroid therapy for severe idiopathic chronic active hepatitis. Chronic active hepatitis. The mayo clinic experience 1986, 269-283. Marcel Dekker, New York. A.J. Czaja, E.R. Dickson (Eds.).
44. Hegarty J.E., Nouri-Aria K.T., Portmann B., et al. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983, 13:685-689.
45. Johnson P.J., McFarlane I.G., Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995, 333:958-963.
46. Kaymakoglu S., Cakaloglu Y., Demir K., et al. Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis?. J Hepatol 1998, 28:78-83.
47. Greeve M., Ferrell L., Kim M., et al. Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes. Hepatology 1993, 17:593-598.
48. Rojkind M., Dunn M. Hepatic fibrosis. Gastroenterology 1979, 76:849-863.
49. Wanless I.R. Use of corticosteroid therapy in autoimmune hepatitis resulting in the resolution of cirrhosis. J Clin Gastroenterol 2001, 32:371-372.
50. Cotler S.J., Jakate S., Jensen D.M. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001, 32:428-430.
51. Czaja A.J., Carpenter H.A. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004, 40:646-652.
52. Ferreira A.R., Roquete M.L., Toppa N.H., et al. Effect of treatment of hepatic histopathology in children and adolescents with autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2008, 46:65-70.
53. Gossard A.A., Lindor K.D. Development of autoimmune hepatitis in primary biliary cirrhosis. Liver Int 2007, 27:1086-1090.
54. Twaddell W.S., Lefkowitch J., Ber P.D. Evolution from primary biliary cirrhosis to primary biliary cirrhosis/autoimmune hepatitis overlap syndrome. Semin Liver Dis 2008, 28(1):128-134.
55. Muratori P., Muratori L., Ferrari R., et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003, 98(2):431-437.
56. Rigopoulou E.I., Davies E.T., Pares A., et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005, 54(4):528-532.
57. Corpechot C., Carrat F., Poupon R., et al. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002, 122:652-658.
58. Gregorio G.V., Portmann B., Karani J., et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001, 33:544-553.
59. Abdalian R., Dhar P., Jhaveri K., et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008, 47:949-957.